Vedolizumab for treating moderately to severely active Crohn's disease after prior therapy

Technology appraisal guidance
Reference number: TA352
Published: 26 August 2015

Crohn's disease (moderate to severe) - vedolizumab: committee papers part 1

Crohn's disease (moderate to severe) - vedolizumab: committee papers part 1

Crohn's disease (moderate to severe) - vedolizumab: committee papers part 1
08 January 2015
(10.23 Mb 50 sec)

Adobe Acrobat reader required.

Adobe Acrobat reader required.

This page was last updated: 09 January 2015